59 results
8-K
EX-99.2
FBRX
Forte Biosciences Inc
18 Mar 24
Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update
4:18pm
GVHD Humanized mouse model of graft vs host disease 26
DOSE-RANGING INVESTIGATION OF FB102 IN A HUMANIZED MOUSE MODEL OF ACUTE GVHD: THERAPEUTIC MODE
DEFA14A
FBRX
Forte Biosciences Inc
1 Sep 23
Additional proxy soliciting materials
5:25pm
and vitiligo
FB-102 IN GRAFT VS HOST DISEASE
DOSE-RANGING INVESTIGATION OF FB102 IN A HUMANIZED MOUSE MODEL OF ACUTE GVHD: THERAPEUTIC MODE
DEFC14A
FBRX
Forte Biosciences Inc
25 Aug 23
Proxy in contested solicitation
10:10am
to Camac’s investigation into possible mismanagement at the Company and widespread stockholder discontent, and that the agreements could result
PRRN14A
FBRX
Forte Biosciences Inc
17 Aug 23
Revised preliminary proxy statement filed by non-management
9:30am
in response to Camac’s investigation into possible mismanagement at the Company and widespread stockholder discontent, and that the agreements could
8-K
EX-10.2
FBRX
Forte Biosciences Inc
1 Aug 23
Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102
4:06pm
or litigation. The indemnification provided for under this Agreement shall remain in full force and effect regardless of any investigation made by or on behalf
8-K
EX-99.2
saee9dbabbsj1lk0oab
1 Aug 23
Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102
4:06pm
8-K
EX-10.1
9lm5myvkut ij8
1 Aug 23
Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102
4:06pm
PREC14A
2h8cfoyhn8hd37zdel8h
25 May 23
Preliminary proxy with contested solicitation
3:51pm
8-K
EX-10.1
jxjueqftkz65tl
31 Mar 22
Entry into a Material Definitive Agreement
8:57pm
8-K
EX-1.1
s4pl 04n68u0
29 Oct 20
Other Events
5:28pm
8-K
EX-10.1
4tzzuuyzkwk0rq6
4 Sep 20
Audited Financial Statements
4:31pm
8-K
EX-5.1
c855inn4zox1t
4 Sep 20
Audited Financial Statements
4:31pm
424B3
1xoie9lmh4a1n ysa2o
14 May 20
Prospectus supplement
12:00am